Chimeric antigen receptor T-cells (CARs) are a new, transformative therapeutic modality that has shown powerful improvements in outcomes for certain blood cancers. Unfortunately, there are toxic side effects and limited efficacy against solid tumors (90% of indications) that will greatly limit the potential of this technology.
Chimera Bioengineering builds control systems that will increase efficacy against solid tumors while limiting toxicity. Unlike other companies that rely on engineered protein control systems, we are the only company to utilize RNA based control systems, which is silent to the immune system, leading to curative potential for these therapies.
We are selfishly passionate about restoring dignity to cancer patients. Our company was founded by a cancer survivor and one who lost his wife to cancer. We've seen the reality of what existing treatments do today. We see the potential of nature's most potent anti-cancer therapy, our own immune systems, as the answer to improving outcomes, while allowing patients and their families to face their journey with more dignity.
Community community community! We could go on and on about the resources that JLABS has provided: lab space, shared equipment, expert advice; but really the difference has been the physical union of like minded entrepreneurs, scientists, operators, JNJ executives, and JLABS staff. It is in this environment that we have exceeded expectations of our progress. It is in this community, that we are able to lean on the advice and support of our sister companies at JLABS, which comprise the world’s experts on antibody development, cancer biology, commercialization, and more. It is this community that makes our company of 10, feel like it has the resources and innovation of hundreds!
Meet the team:
From right to Left:
Jay Danao, Scientist; Melissa Fardy, Scientist; Gus Zeiner, CSO; Krista McNally, scientist; Joe Solvason, Scientist; Ben Wang, CEO